These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8927904)

  • 1. [Secondary prevention of arteriosclerosis].
    Hoffmann U; Leu AJ
    Praxis (Bern 1994); 1996 Sep; 85(39):1201-5. PubMed ID: 8927904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A; Poredos P
    Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of coronary artery disease.
    Hall SL; Lorenc T
    Am Fam Physician; 2010 Feb; 81(3):289-96. PubMed ID: 20112887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical risk factors and emerging elements in the risk profile for coronary artery disease.
    Gensini GF; Comeglio M; Colella A
    Eur Heart J; 1998 Feb; 19 Suppl A():A53-61. PubMed ID: 9519344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of atherosclerotic carotid stenoses].
    Mas JL
    Rev Prat; 1993 Dec; 43(19):2504-8. PubMed ID: 8153533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic drugs for the secondary prevention of ischemic stroke.
    Nenci GG; Goracci S
    Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
    Aumont MC; Seknadji P
    Arch Mal Coeur Vaiss; 1996 Aug; 89 Spec No 3():39-41. PubMed ID: 8949317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
    Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
    Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical considerations in cardiovascular prevention.
    Follath F
    Fundam Clin Pharmacol; 2009 Dec; 23(6):669-73. PubMed ID: 19500153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of risk factors of coronary atherosclerosis].
    Guize L; Iliou MC
    Arch Mal Coeur Vaiss; 1992 Nov; 85(11 Suppl):1687-93. PubMed ID: 1304142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.